

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934**

Dated March 2, 2016

Commission File Number 001-36421

---

**AURINIA PHARMACEUTICALS INC.**

(Exact name of Registrant as specified in its charter)

---

N/A

(Translation of Registrant's Name)

#1203-4464 Markham Street  
Victoria, British Columbia  
V8Z7X8

(250) 708-4272

(Address and telephone number of registrant's principle executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 2, 2016

**Aurinia Pharmaceuticals Inc.**

By: /s/ Michael R. Martin

Name: Michael R. Martin

Title: Chief Operating Officer

**EXHIBIT INDEX**

<b>Exhibit</b>	<b>Description of Exhibit</b>
99.1	News Release – AURINA RECEIVES FDA FAST TRACK DESIGNATION FOR VOCLOSPORIN FOR THE TREATMENT OF LUPUS NEPHRITIS

## Aurina Receives FDA Fast Track Designation for *Voclosporin* for the Treatment of Lupus Nephritis

VICTORIA, British Columbia--(BUSINESS WIRE)--March 2, 2016--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for *voclosporin*, the Company’s next generation calcineurin inhibitor, for the treatment of Lupus Nephritis (LN).

The Fast Track program was created by the FDA to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address significant unmet medical needs. Compounds that receive this FDA designation benefit from more frequent meetings and communications with the FDA to review the drug’s development plan including the design of clinical trials and the use of biomarkers to support approval. Additionally, Fast Track designation allows the Company to submit parts of the New Drug Application (NDA) on a rolling basis for review as data becomes available.

The Company’s 265 patient Phase 2b trial, called AURA (Aurinia Urine protein Reduction in Active Lupus with *voclosporin*) has recently completed enrollment and is currently underway in over 20 countries worldwide. It is a randomized, controlled, double-blind study comparing the efficacy of two doses of *voclosporin* plus mycophenolate mofetil (MMF) vs. MMF alone in patients with active LN. There will be a primary analysis to determine complete remission at week 24 and various secondary analyses at week 48 which include biomarkers and markers of non-renal SLE. The Company expects to analyse and review the AURA data with the FDA later in 2016 in order to reach agreement on further clinical development requirements.

“It is encouraging that Fast Track designation has been granted for *voclosporin* and we look forward to working closely with FDA as we complete the AURA trial. This designation demonstrates the substantial unmet medical need for patients with LN and potentially helps move a promising therapy through the FDA more rapidly.” said Lawrence Mandt, Aurinia’s Vice President of Regulatory Affairs & Quality.

### **About Aurinia**

Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. The fully-enrolled Phase 2b AURA-LV clinical trial is evaluating the efficacy of its lead drug, *voclosporin*, as a treatment for active LN. LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.

*Voclosporin* is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with extensive clinical data in over 2,000 patients in other indications. *Voclosporin* is made by a modification of a single amino acid of the cyclosporine molecule (a CNI approved for use in transplant patients since 1983). This modification results in a more predictable pharmacokinetic and pharmacodynamic relationship, an increase in potency vs. cyclosporine, an altered metabolic profile, and potential for flat dosing.

### **About AURA:**

The AURA study or “Aurinia Urine Protein Reduction in Active Lupus Nephritis Study” is an adequate and well-controlled clinical trial that enrolled 265 patients and is being conducted in over 20 countries worldwide. This trial will compare the efficacy of *voclosporin* against placebo in achieving remission in patients with active lupus nephritis. The AURA study is designed to demonstrate that *voclosporin* can induce a rapid and sustained reduction of proteinuria in the presence of extremely low steroid exposure. It will compare two dosage groups of *voclosporin* (23.7mg and 39.5mg) compared to placebo, with all patients receiving mycophenolate mofetil (MMF) and oral corticosteroids as background therapy. There will be a primary analysis to determine complete remission at week 24 (confirmed at 26 weeks) and various secondary analyses at week 48 which include biomarkers and markers of non-renal SLE.

*We seek Safe Harbor.*

### **CONTACT:**

Aurinia Pharmaceuticals Inc.  
Mr. Michael Martin, 250-708-4272  
Chief Operating Officer  
Fax: 250-744-2498  
[mmartin@auriniapharma.com](mailto:mmartin@auriniapharma.com)

or

Renmark Financial Communications Inc.  
Barry Mire, 416-644-2020  
[bmire@renmarkfinancial.com](mailto:bmire@renmarkfinancial.com)

or

Laura Welsh, 514-939-3989  
[lwelsh@renmarkfinancial.com](mailto:lwelsh@renmarkfinancial.com)